Securities Code: 002412 Securities Abbreviation: Hansen Pharmaceutical Announcement No.: 2026-010 Hunan Hansen Pharmaceutical Co., Ltd. Announcement on Changes to Accounting Policies The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from false records, misleading statements, or material omissions.
Special Reminder: Hunan Hansen Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has made corresponding changes in accordance with the relevant Enterprise Accounting Standards Interpretations issued by the Ministry of Finance of the People's Republic of China (hereinafter referred to as the "Ministry of Finance"). This matter does not require submission to the Company's Board of Directors and Shareholders' Meeting for deliberation and will not have a significant impact on the Company's financial position, operating results, and cash flows.
I. Overview of the Current Accounting Policy Change
(I) Reason for Change and Effective Date On December 5, 2025, the Ministry of Finance issued "Enterprise Accounting Standards Interpretation No. 19" (Cai Kuai [2025] No. 32), which stipulates that the accounting treatment for compensatory assets in business combinations not under common control, the accounting treatment for relevant capital reserves upon disposal of subsidiaries acquired through business combinations under common control, the termination of recognition of financial liabilities settled by electronic payment systems, the assessment of characteristics of contractual cash flows of financial assets and related disclosures, and the disclosure of equity instruments designated at fair value through other comprehensive income will be effective from January 1, 2026.